ClinicalTrials.gg

Program

azilsartan medoxomil

Also written as “Azilsartan medoxomil and chlorthalidone”, “Azilsartan medoxomil” and “Azilsartan Medoxomil”.

Its studies are mostly in Essential Hypertension · Hypertension · Renal Insufficiency, led by 3 companies.

Furthest: phase 4, since Jun 24, 201525 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda230 open or runningphase 4since Jun 24, 2015Aug 7, 2006none ahead
Azurity Pharmaceuticals10 open or runningphase 3since Sep 8, 2014Sep 8, 2014none ahead
Gedeon Richter Plc.11 open or runningphase 1since Apr 28, 2025Apr 28, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Aug 7, 2006.

  1. Jan 7, 2009Phase 3 study in Essential HypertensionTakeda · NCT00818883 · 609 enrolled · United States, Russian Federation
  2. Feb 13, 20092 phase 3 studiesTakeda · NCT00846365, NCT00847626
  3. Oct 12, 2009Phase 3 study in Essential HypertensionTakeda · NCT00996281 · 837 enrolled · Austria, Germany, Netherlands and more
  4. Dec 14, 2009Phase 3 study in Essential HypertensionTakeda · NCT01033071 · 1,071 enrolled · United States, Canada
  5. Feb 26, 2010Phase 1 study in HypertensionTakeda · NCT01078376 · 29 enrolled · United States, United Kingdom
  6. Mar 4, 2011Phase 3 study in Renal InsufficiencyTakeda · NCT01309828 · 153 enrolled · Bulgaria, Germany, Latvia and more
  7. Oct 18, 2011Phase 3 study in Essential HypertensionTakeda · NCT01456169 · 507 enrolled · Bulgaria, Estonia, France and more
  8. Dec 18, 2011Phase 3 study in HypertensionTakeda · NCT01496430 · 105 enrolled · United States
  9. Jul 28, 2014Phase 3 study in HypertensionTakeda · NCT02203916 · 328 enrolled · Korea, Republic of
  10. Sep 8, 2014Azurity Pharmaceuticals’ first study: phase 3 study in HypertensionNew to Azurity PharmaceuticalsAzurity Pharmaceuticals · NCT02235909 · 377 enrolled · United States, Argentina, Brazil and more
  11. Jun 22, 2015Phase 3 study in Essential HypertensionTakeda · NCT02480764 · 612 enrolled · China
  12. Jun 24, 2015Phase 4 study in Essential HypertensionTakeda · NCT02517866 · 380 enrolled · China, Taiwan, Thailand
  13. Sep 2, 2015Phase 1 study in Healthy VolunteerTakeda · NCT02541669 · 64 enrolled · China
  14. Apr 28, 2025Gedeon Richter Plc.’s first study: phase 1 study in HypertensionNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT06990204 · 56 planned · Russian Federation

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
TelmisartanruleBoehringer Ingelheimphase 4132
LosartanruleOrganonphase 458
sparsentanruletravere-therapeutics-incphase 49

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06990204Hypertension · Russian Federation1Not yet recruitingGedeon Richter Plc.Jul 1, 202556
NCT02541669Healthy Volunteer · China1CompletedTakedaMar 17, 201764
NCT02517866Essential Hypertension · China, Taiwan, Thailand4CompletedTakedaNov 15, 2016380
NCT02480764Essential Hypertension · China3CompletedTakedaSep 22, 2017612
NCT02235909Hypertension · United States, Argentina, Brazil and more3CompletedAzurity PharmaceuticalsNov 11, 2019377
NCT02203916Hypertension · Korea, Republic of3CompletedTakedaJan 2016328
NCT01496430Hypertension · United States3TerminatedTakedaMay 2013105
NCT01456169Essential Hypertension · Bulgaria, Estonia, France and more3CompletedTakedaDec 2012507
NCT01309828Renal Insufficiency · Bulgaria, Germany, Latvia and more3CompletedTakedaOct 2012153
NCT01078376Hypertension · United States, United Kingdom1TerminatedTakedaJul 201329
NCT01033071Essential Hypertension · United States, Canada3CompletedTakedaOct 20101,071
NCT00996281Essential Hypertension · Austria, Germany, Netherlands and more3CompletedTakedaNov 2011837
NCT00847626Hypertension · United States, Chile, Mexico and more3CompletedTakedaMay 20101,711
NCT00846365Essential Hypertension · United States, Chile, Mexico3CompletedTakedaJun 20101,085
NCT00818883Essential Hypertension · United States, Russian Federation3CompletedTakedaNov 2009609
NCT00760214Hypertension · Bulgaria, Estonia, Finland and more3CompletedTakedaApr 2009885
NCT00696436Hypertension · United States, Argentina, Brazil and more3CompletedTakedaAug 20091,291
NCT00696384Hypertension · United States, Argentina, Mexico3CompletedTakedaApr 2009418
NCT00696241Hypertension · United States, Argentina, Mexico3CompletedTakedaOct 20081,275
NCT00695955Hypertension · United States, Chile, Mexico3CompletedTakedaMay 2010669
NCT00591773Hypertension · United States3CompletedTakedaMar 2009551
NCT00591578Hypertension · United States, Chile, Mexico and more3CompletedTakedaSep 2009984
NCT00591266Hypertension · United States3CompletedTakedaMar 2009566
NCT00591253Hypertension · United States, Puerto Rico3CompletedTakedaApr 2009413
NCT00362115Hypertension · United States, Argentina, Mexico and more2CompletedTakedaDec 2006449

How it is read

Names in the registry

  • “Azilsartan medoxomil and chlorthalidone”, 15 entries
  • “Azilsartan medoxomil”, 14 entries
  • “Azilsartan Medoxomil”, 8 entries
  • “Azilsartan medoxomil (TAK-491)”, 4 entries
  • “Azilsartan medoxomil and olmesartan”, 3 entries

Codes read as this program: AR14, TAK491CLD.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.